Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$30.50 USD
-0.04 (-0.13%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $30.51 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
XENE 30.50 -0.04(-0.13%)
Will XENE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Other News for XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE ...
Xenon Pharmaceuticals Inc (XENE) Announces Equity Inducement Grants | XENE stock news
BlackRock, Inc. Expands Stake in Xenon Pharmaceuticals Inc.
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
COMMODORE CAPITAL LP Acquires 1,175,000 Shares in Cidara Therapeutics Inc